Why Life Sciences Software Companies Keep Losing Their Best Product Leaders to Pharma

There is a structural talent drain in life sciences software that most companies in the sector are aware of but few have figured out how to stop. The best product leaders - the ones who understand both the technology and the regulatory context their products operate in - keep leaving for pharma and biotech.

Not for other software companies. For the customers.

This is not a compensation problem, although compensation plays a role. It is a structural problem rooted in how life sciences software companies are organised, how they define product leadership roles, and what career trajectory they offer to the people who are most valuable to them.

The Profile That Gets Poached

The specific talent that pharma and biotech companies are targeting is not generic product management. It is a very particular profile: product leaders who are fluent in GxP regulatory frameworks, who understand how their software is actually used in validated environments, and who can translate between technical engineering teams and scientific or regulatory end users.

These are people who understand 21 CFR Part 11 not as an abstract compliance requirement but as a design constraint that shapes every product decision. They understand GAMP 5 validation categories. They know what an audit trail needs to capture and why. They understand the difference between how a LIMS is supposed to work and how it actually works in a QC release lab at 2am during a batch crisis.

This combination of product thinking and regulatory domain expertise takes years to develop. A product leader who joins a life sciences software company from a general SaaS background needs 18 to 24 months just to become conversant in the regulatory context. To become genuinely fluent - to be the person in the room who can make product decisions that account for validation impact, regulatory submission requirements, and real-world laboratory workflow - takes three to five years.

By the time a product leader reaches that level of fluency, they have become exactly the person that pharma and biotech companies want to hire as a Head of Digital, VP of IT, or Director of Lab Informatics. The customer has watched this person understand their problems better than their own internal teams do, and they want that person on their side of the table.

Why They Leave

The pull factors from pharma are well understood. Higher total compensation, particularly at the VP level and above. Broader scope of responsibility. The appeal of working on products that directly impact patient outcomes rather than selling tools to people who do. These are real and legitimate motivations.

But the push factors from life sciences software companies are equally important, and less frequently discussed.

Limited career progression. Many life sciences software companies are mid-cap or private equity-backed businesses with relatively flat organisational structures. A VP of Product at a 500-person LIMS company may have nowhere to go. The CEO role is not on offer. The CTO role is a different skill set. The CPO title may already exist and be occupied. The result is a talented person in a role they have outgrown, with no clear path to a larger scope within the same organisation.

Product roadmap constraints. Product leaders in life sciences software often find themselves spending more time managing technical debt, maintaining legacy validated systems, and navigating the constraints of regulated software development than they spend on genuine product innovation. The validation overhead is real. Every change to a GxP-validated product requires impact assessment, regression testing, and documentation that can consume 40% or more of the development cycle. For a product leader who wants to build, this becomes frustrating over time.

Distance from impact. Life sciences software product leaders are two steps removed from the patient. They build tools that are used by scientists and quality professionals who work on therapies that treat patients. This level of indirection is fine for some people. For others, particularly those who developed their regulatory fluency because they genuinely care about the science, the opportunity to work directly on a therapeutic programme - to be in the room where decisions about clinical development are made - is compelling in a way that selling software licences never will be.

Compensation gaps at senior levels. While life sciences software companies offer competitive base salaries and often include equity or bonus structures, the total compensation packages at VP and above in pharma and biotech can be significantly higher. A VP of Digital Transformation at a mid-cap pharma company may command 30% to 50% more in total compensation than a VP of Product at the software company that sold them their LIMS. When a recruiter calls with that number, it is hard to say no.

What Software Companies Can Do

The companies that retain their best product leaders tend to share a few characteristics.

They create genuine executive-level product roles with strategic authority, not just operational responsibility. The difference matters. A VP of Product who owns the roadmap, has a seat at the executive table, and can influence company strategy is in a fundamentally different position from one who manages a backlog and reports to a CTO who makes the real decisions.

They invest in the product leader's external visibility. Conference speaking, thought leadership, industry advisory board participation, and direct relationships with key customers all create professional capital that makes the role more valuable beyond its title and compensation. A product leader who is known in the industry has something to lose by leaving.

They structure compensation to compete with pharma at the senior level, not just at the mid-level. This may mean equity participation, long-term incentive plans, or retention packages that acknowledge the market reality. Matching pharma dollar for dollar may not be possible, but closing the gap enough to make the decision difficult is achievable.

They give product leaders room to innovate. This means carving out development capacity that is not consumed by maintenance, validation overhead, or customer-specific customisation requests. It means allowing the product leader to pursue a vision for the product that goes beyond the current customer base's feature requests.

If You Are Hiring Product Leaders in Life Sciences Software

The talent pool for GxP-fluent product leaders is small, and it is getting smaller as pharma continues to absorb the best people from the software side. If you are a life sciences software company looking for senior product leadership, or a pharma company looking to hire from the software sector, we would welcome a confidential conversation. ProGen Search runs retained executive searches across the life sciences software sector.

Byron Fitzgerald is the Founder of ProGen Search, a retained executive search and market intelligence firm serving life sciences, radiopharma, CDMO, ADC, and cell and gene therapy sectors.